Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AUPH 
Aurinia Pharmaceuticals Inc (AUPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: AUPH (3-star) is a STRONG-BUY. BUY since 22 days. Simulated Profits (13.21%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.5
1 Year Target Price $16.5
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.72% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.10B USD | Price to earnings Ratio 28.93 | 1Y Target Price 16.5 |
Price to earnings Ratio 28.93 | 1Y Target Price 16.5 | ||
Volume (30-day avg) 6 | Beta 1.46 | 52 Weeks Range 6.55 - 16.48 | Updated Date 12/3/2025 |
52 Weeks Range 6.55 - 16.48 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate 0.16 | Actual 0.23 |
Profitability
Profit Margin 29.28% | Operating Margin (TTM) 40.49% |
Management Effectiveness
Return on Assets (TTM) 9.41% | Return on Equity (TTM) 20.65% |
Valuation
Trailing PE 28.93 | Forward PE 21.01 | Enterprise Value 1858265839 | Price to Sales(TTM) 7.89 |
Enterprise Value 1858265839 | Price to Sales(TTM) 7.89 | ||
Enterprise Value to Revenue 6.99 | Enterprise Value to EBITDA 17.95 | Shares Outstanding 131840559 | Shares Floating 128247904 |
Shares Outstanding 131840559 | Shares Floating 128247904 | ||
Percent Insiders 7.14 | Percent Institutions 50.79 |
Upturn AI SWOT
Aurinia Pharmaceuticals Inc
Company Overview
History and Background
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company founded in 2003. It focuses on developing and commercializing therapies to treat autoimmune diseases, particularly lupus nephritis (LN). The company's significant milestone was the FDA approval of LUPKYNIS for LN in 2021.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of therapies for autoimmune diseases, with a primary focus on lupus nephritis.
- Commercial Operations: Handles the marketing, sales, and distribution of LUPKYNIS in the United States and other territories.
Leadership and Structure
Peter Greenleaf is the President and CEO. The company operates with a functional structure, including departments for research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- LUPKYNIS (voclosporin): LUPKYNIS is an oral medication approved for the treatment of adult patients with active lupus nephritis (LN). While specific market share data is not readily available publicly, LUPKYNIS is positioned as a leading therapy in the LN market. Competitors include Benlysta (belimumab) by GSK and other immunosuppressants like cyclophosphamide and mycophenolate mofetil.
Market Dynamics
Industry Overview
The pharmaceutical industry for autoimmune diseases is growing, driven by the increasing prevalence of these conditions and advancements in treatment options. Lupus nephritis is a significant area of unmet need, with a substantial patient population seeking effective therapies.
Positioning
Aurinia is positioned as a key player in the lupus nephritis market with LUPKYNIS. Its competitive advantage lies in the drug's specific efficacy profile and oral administration.
Total Addressable Market (TAM)
The TAM for lupus nephritis treatments is estimated to be in the billions of dollars annually. Aurinia, with LUPKYNIS, aims to capture a significant portion of this market through continued sales growth and market penetration.
Upturn SWOT Analysis
Strengths
- FDA-approved LUPKYNIS for lupus nephritis
- Strong clinical data supporting LUPKYNIS efficacy
- Experienced management team
- Focus on a specific disease area (lupus nephritis)
Weaknesses
- Reliance on a single product (LUPKYNIS)
- Limited commercial infrastructure compared to larger pharmaceutical companies
- High operating expenses related to drug development and commercialization
- Dependence on successful market adoption of LUPKYNIS
Opportunities
- Expanding LUPKYNIS into new markets (e.g., Europe, Asia)
- Developing new formulations or indications for voclosporin
- Acquiring or partnering with other companies in the autoimmune disease space
- Increasing awareness and diagnosis of lupus nephritis
Threats
- Competition from existing and emerging therapies for lupus nephritis
- Regulatory hurdles and potential delays in market access
- Pricing pressures from healthcare providers and payers
- Adverse events or safety concerns related to LUPKYNIS
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Aurinia's advantage lies in the specific approval of LUPKYNIS for LN and its oral formulation. Disadvantages include its smaller size and commercial infrastructure compared to larger competitors like GSK and BMS. GSK's Benlysta has a broader lupus indication but a different mechanism of action.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by the launch and sales growth of LUPKYNIS. The rate of growth depends on market penetration and expansion.
Future Projections: Future growth projections rely on analyst estimates, which consider factors like LUPKYNIS sales, market expansion, and potential new indications. These are not accessible in real time.
Recent Initiatives: Recent initiatives include efforts to increase LUPKYNIS adoption, expand into new markets, and conduct further clinical research on voclosporin.
Summary
Aurinia Pharmaceuticals is a company centered around LUPKYNIS, its primary drug for lupus nephritis. While LUPKYNIS sales drive revenue, the company remains reliant on a single product. Expansion into new markets and exploration of new indications for voclosporin could enhance growth, but competition and regulatory hurdles need to be carefully managed. Financial performance hinges on the successful adoption and market penetration of LUPKYNIS.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Aurinia Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q reports)
- Analyst Reports (FactSet, Bloomberg)
- Company Press Releases
- PubMed
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurinia Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 1999-01-26 | President, CEO & Director Mr. Peter S. Greenleaf M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.auriniapharma.com |
Full time employees 130 | Website https://www.auriniapharma.com | ||
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.